News & Events

News & Events

The latest press releases and publications from Onco3R Therapeutics.
Stay in the loop with our latest company milestones!

Onco3R Therapeutics at the AACR-NCI-EORTC Meeting in Boston

Evelien Micholt 10/25/25 Evelien Micholt 10/25/25

Onco3R Therapeutics at the AACR-NCI-EORTC Meeting in Boston

Onco3R Therapeutics reports first pre-clinical data from its best-in-class precision oncology portfolio at the 2025 AACR-NCI-EORTC symposium

Evelien Micholt 10/22/25 Evelien Micholt 10/22/25

Onco3R Therapeutics reports first pre-clinical data from its best-in-class precision oncology portfolio at the 2025 AACR-NCI-EORTC symposium

First pre-clinical data from best-in-class precision oncology portfolio at 2025 AACR-NCI-EORTC symposium

Onco3R Therapeutics Announces Completion of First Cohort in Phase 1 Trial of Novel SIK3 inhibitor O3R-5671 and Oral Presentation at UEGW 2025

Evelien Micholt 10/6/25 Evelien Micholt 10/6/25

Onco3R Therapeutics Announces Completion of First Cohort in Phase 1 Trial of Novel SIK3 inhibitor O3R-5671 and Oral Presentation at UEGW 2025

Completion of first cohort

Discovery of a novel, selective SIK3 inhibitor for the treatment of ulcerative colitis, Crohn’s disease and other autoimmune diseases

Evelien Micholt 10/6/25 Evelien Micholt 10/6/25

Discovery of a novel, selective SIK3 inhibitor for the treatment of ulcerative colitis, Crohn’s disease and other autoimmune diseases

O3R-5671

Looking to meet us? Find us at these events

Evelien Micholt 9/18/25 Evelien Micholt 9/18/25

Looking to meet us? Find us at these events

Events

Approval of First Clinical Trial Application for Novel SIK inhibitor O3R-5671 in Autoimmune Diseases</span>

Evelien Micholt 9/4/25 Evelien Micholt 9/4/25

Approval of First Clinical Trial Application for Novel SIK inhibitor O3R-5671 in Autoimmune Diseases

Approval First Clinical Trial Application